- Advertisement -
Reading Time: 1 minute


Datatrak International, Inc. (OTC Markets: DTRK), a worldwide Software-as-a-Service (SaaS) provider and innovation leader of cloud-based technologies for the life sciences industry, today announced that CEO Jim Bob Ward will be speaking at the 2019 China DIA Annual Meeting in Beijing, China on May 23rd.

Mr. Ward will be presenting during the session on Artificial Intelligence applications in Clinical Trials on the topic of ‘Embedding Big Data Analytics into Cloud Platforms to Improve Clinical Trial Performance with Business Intelligence.’ “Everything is changing, the Enterprise Cloud is moving beyond metric-driven dashboards, intelligent workflows, and trial performance analytics. Our platform will soon help sponsors centralize study data across vendors for both self-driven scientific research and machine learning predictive analytics on clinical data and images.”

“Our presence in the APAC region continues to grow and we see an increase in the usage of our Datatrak Enterprise Platform, which provides clients a complete portfolio of software products in multiple languages,” said Scott DeMell, VP Sales at Datatrak.  “The opportunity to speak at the event on the important topic of Artificial Intelligence in clinical trials continues to reinforce Datatrak’s unique quality of a unified platform with products and features clients can use to consolidate and evaluate their data to further their research.”

The DIA China 2019 Annual Meeting from May 20 – 23 is the largest event in the life sciences industry, designed to foster the international exchange of actionable insights to improve health globally through the advancement of lifesaving medicines and technologies in the APAC region, bringing together 3000+ pharmaceutical R&D professionals involved at all levels of the health care product development spectrum.

Book an appointment with Datatrak at DIA China to see the Multi-Lingual Enterprise Cloud Platform in action.


SOURCE Datatrak International, Inc.

- Advertisement -


Please enter your comment!
Please enter your name here